Diprenorphine

DB01548IllicitInvestigationalVet approvedSmall molecule

A narcotic antagonist similar in action to naloxone. It is used to remobilize animals after etorphine neuroleptanalgesia and is considered a specific antagonist to etorphine. [PubChem].

Mechanism: Diprenorphine binds approximately equally to the three subtypes of opioid receptorsand antagonizes them.
Curator reviewed
Primary indication: Diprenorphine is indicated to reverse the effects of powerful opioids including etorphine and carfentanil, often used for tranquilizing large animals.Curator reviewed
Formula / weight: C₂₆H₃₅NO₄ · 425.569 g/mol (avg)
Also known as: Diprenorfin
Code names: M-5050

Resolves to

Compound

UNII1F0L5N25ZZCAS14357-78-9ChEMBLCHEMBL281786ChEBI4650PubChem443408KEGGC11794

Structure

InChIKeyOIJXLIIMXHRJJH-KNLIIKEYSA-NSMILES[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(CC3CC3)[C@]([H])(C4)[C@]11CC[C@@]2(OC)[C@H](C1)C(C)(C)O

Targets

P35372OPRM1P41143OPRD1P41145OPRK1O60858TRIM13

What you can answer from here — as of September 16, 2026

4Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

54Drug interactionsStructured to mechanism, not free text

1Clinical trialPhase, status and sponsor resolved per trial

24+ReferencesStructured and connected to the statements they support

Which drugs share a target with Diprenorphine, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account